title: Management of urticaria: a consensus report.
abstract: This consensus report is the result of a panel discussion during the International Clinically Oriented ESDR Symposium Urticaria 2000. Urticaria has a profound impact on the quality of life and effective treatment is required. The most important are nonsedating H1 antihistamines. They have been proven to be effective in double-blind controlled studies, but concentrations higher than those recommended may be necessary. Due to different urticaria subtypes and the individual variation in the course of the disease and response to treatment, however, alternative therapies may be required. Immunosuppressive drugs like cyclosporine A and corticosteroids should not be used long term due to undesirable side-effects.
authors.affiliation: Department of Dermatology and Allergy, Charité, Humboldt University, Berlin, Germany. torsten.zuberbier@charite.de
authors.forename: T
authors.initials: T
authors.lastname: Zuberbier
authors.forename: M W
authors.initials: MW
authors.lastname: Greaves
authors.forename: L
authors.initials: L
authors.lastname: Juhlin
authors.forename: H
authors.initials: H
authors.lastname: Merk
authors.forename: G
authors.initials: G
authors.lastname: Stingl
authors.forename: B M
authors.initials: BM
authors.lastname: Henz
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D004032:Diet; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D011701:PUVA Therapy / Q000379:methods; D010812:Physical Stimulation / Q000009:adverse effects; D010956:Plasmapheresis; D011788:Quality of Life; D014581:Urticaria / Q000517:prevention & control / Q000628:therapy*
chemical_list: D000305:Adrenal Cortex Hormones; D006634:Histamine H1 Antagonists; D007166:Immunosuppressive Agents; D016572:Cyclosporine